Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, sec-filing
TL;DR
Keros Therapeutics filed an 8-K on 7/17/25, standard corporate update.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on July 17, 2025, reporting other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and principal executive offices in Lexington, Massachusetts.
Why It Matters
This 8-K filing serves as an official record of Keros Therapeutics' corporate and financial reporting activities with the SEC.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- July 17, 2025 (date) — Date of earliest event reported
- Lexington, Massachusetts (location) — Principal executive offices
- 001-39264 (company_id) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Keros Therapeutics, Inc.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 17, 2025.
When was the earliest event reported in this filing?
The earliest event reported was on July 17, 2025.
Where are Keros Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the Commission File Number for Keros Therapeutics, Inc.?
The Commission File Number is 001-39264.
What is the fiscal year end for Keros Therapeutics, Inc.?
The fiscal year end for Keros Therapeutics, Inc. is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Keros Therapeutics, Inc. (KROS).